NextPlat (NXPL) Income from Discontinued Operations (2010)
NextPlat's (NXPL) quarterly Income from Discontinued Operations came in at $327393.0 in Q4 2010, up 123.04% quarter-over-quarter from -$1.4 million in Q3 2010.
Analysis
NextPlat (NXPL) Income from Discontinued Operations (2010) Analysis & Trends
NextPlat (NXPL) has reported Income from Discontinued Operations for 1 consecutive years, with $327393.0 the latest figure, recorded in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | - |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | - |